Emily Archbald, MD
Dermatology · Oklahoma City, OKNPI 1366647026
Payments from drug & device makers
Across 500 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AbbVie$1K
- Pfizer$1K
- Sanofi$778
- E.r. Squibb & Sons, L.L.C.$668
- Johnson & Johnson$602
- plus $3K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 98 | $1,327 |
| AbbVie | 79 | $1,303 |
| Pfizer | 73 | $1,220 |
| Sanofi | 41 | $778 |
| E.r. Squibb & Sons, L.L.C. | 38 | $668 |
| Johnson & Johnson | 39 | $602 |
| UCB, Inc. | 27 | $577 |
| Galderma Laboratories, L.p. | 12 | $253 |
| Arcutis Biotherapeutics, Inc. | 24 | $244 |
| Regeneron Healthcare Solutions, Inc. | 10 | $214 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $202 |
| Dermavant Sciences, Inc. | 11 | $170 |
| LEO Pharma Inc. | 10 | $167 |
| Dermira, Inc. | 1 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Incyte Corporation | 5 | $84 |
| Mayne Pharma Commercial LLC | 5 | $73 |
| VYNE Pharmaceuticals Inc. | 4 | $71 |
| Sun Pharmaceutical Industries Inc. | 3 | $62 |
| Lilly USA, LLC | 3 | $45 |
| Organon | 3 | $30 |
| Botanix SB Inc | 1 | $24 |
| Almirall LLC | 1 | $23 |
| Verrica Pharmaceuticals Inc. | 1 | $21 |
| Amgen | 1 | $18 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $11 |
| Biofrontera Inc. | 1 | $9 |
| Prugen, Inc. Pharmaceuticals | 1 | $5 |
How this compares
$8,457 in reported general payments places this provider in the 70th percentile of 114 dermatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Oklahoma City
- Jarad LevinOklahoma City$1.2M
- Yaohan LamOklahoma City$1.1M
- Julie Bowman LoweOklahoma City$227K
- Kimberly JerdanOklahoma City$59K
- Mark DawkinsOklahoma City$56K
- Stacie RougasOklahoma City$50K
- Clifford HendersonOklahoma City$45K
- Quy PhamOklahoma City$14K
- Sunita CrittendenOklahoma City$13K
- Tiffany BrazealOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.